Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a 63.22%-owned subsidiary of China Resources Pharmaceutical Group Limited, reported unaudited preliminary financial results for 2025 showing solid top-line growth but more modest gains in profitability. Total operating revenue rose 14.53% year on year to RMB 31.63 billion, while operating profit and total profit increased by 8.34% and 5.81%, respectively. Net profit attributable to shareholders edged up 1.60% to RMB 3.42 billion, and net profit excluding extraordinary items grew 1.23%, indicating some margin pressure despite revenue expansion. The company’s total assets jumped 46.72% to RMB 58.81 billion and equity attributable to shareholders climbed 11.40%, supported by a 29.58% increase in share capital, although net assets per share fell 14.06% and weighted average return on equity declined by 1.25 percentage points to 16.08%. These trends suggest that while CR Sanjiu is expanding its scale and asset base, returns on capital are moderating, a dynamic that investors and other stakeholders will watch closely when the audited annual report is released.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate whose businesses span the manufacture and distribution of medicines and healthcare products in mainland China. Its subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), listed on the Shenzhen Stock Exchange, is a key platform for the group’s pharmaceutical operations and contributes significantly to its revenues and earnings in the Chinese healthcare market.
Average Trading Volume: 12,510,133
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.15B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.